HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SUPN
Indivior Pharmaceuticals Inc
SUPN's fundamentals are strong and it looks cheap: trading at 8.2x earnings, about a third of its usual 26x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SUPN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Under pressure | |
| Healthy |
SUPN's revenue, profitability and balance sheet are currently healthy, but its cash flow is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SUPN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.4x | $29.20 | — |
| Current | 8.2x | $29.20 | — |
| Cheap | 18x | $63.68 | +118% |
| Fair | 26x | $91.92 | +215% |
| Expensive | 97x | $347 | +1088% |
Historical ranges are pointers, not guarantees.
SUPN's PE is in its cheap range at 8.2x. If earnings grow as analysts expect, today's price would be 7.4x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SUPN Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for SUPN, but weaker profitability. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SUPN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.97 | +11% |
| Q3 2026 | $3.58 | +175% |
| Q2 2026 | $2.79 | +179% |
| Q1 2026 | $1.95 | +1293% |
| Q4 2025 | $1.64 | +681% |
| Q3 2025 | $1.30 | +829% |
| Q2 2025 | $1.00 | +$1.83 |
| Q1 2025 | $0.14 | -18% |
| Q4 2024 | $0.21 | +425% |
SUPN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SUPN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SUPN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $356M | +13% |
| Q2 2026 | $343M | +14% |
| Q1 2026 | $317M | +19% |
| Q4 2025 | $358M | +20% |
| Q3 2025 | $314M | +2.3% |
| Q2 2025 | $302M | +1% |
| Q1 2025 | $266M | -6.3% |
| Q4 2024 | $299M | +2% |
SUPN's revenue has grown year over year for six quarters in a row: $356M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 51% | +37 points |
| Q2 2026 | 47% | +23 points |
| Q1 2026 | 43% | +18 points |
| Q4 2025 | 23% | -9.5 points |
| Q3 2025 | 14% | +12 points |
| Q2 2025 | 24% | +63 points |
| Q1 2025 | 25% | -1.6 points |
| Q4 2024 | 32% | +11 points |
SUPN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SUPN on cash flow, with more consistent year-over-year improvement.
SUPN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $83M | +$142M |
| Q2 2026 | $222M | +57% |
| Q1 2026 | -$29M | -141% |
| Q4 2025 | -$245M | -$224M |
| Q3 2025 | -$59M | -$54M |
| Q2 2025 | $141M | +68% |
| Q1 2025 | $70M | +$110M |
| Q4 2024 | -$21M | +$278M |
SUPN has burned cash in most quarters: $31M over the past year, down 76% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SUPN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SUPN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -2M shares |
| 1 year | -5.4% | -7M shares |
| 3 years | -11% | -15.7M shares |
SUPN has 122M diluted shares, down 5.4% from a year ago, with $303M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $177M |
| Q1 2026 | $126M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $11M |
| Q4 2024 | $51M |
SUPN spent $303M buying back its own shares over the past year, about five times what it spent the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SUPN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.7x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | 0.5x | Very low |
SUPN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SUPN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.4 | Neutral |
| Stochastic | 32.2 | Neutral |
SUPN's weekly RSI is 40 (neutral) and its Stochastic is 32 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SUPN PE vs Healthcare Sector
| Metric | SUPN | Sector median | Relative |
|---|---|---|---|
| PE | 8.2x | 26x | 68% below |
| PE % | 1 | 29 | 28 pts below |
SUPN is trading at 8.2x earnings, a 68% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SUPN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.3 | 19% below |
| 20 week MA | $37.3 | 22% below |
| 50 week MA | $35.8 | 18% below |
| 100 week MA | $26.3 | 11% above |
| 200 week MA | $21.9 | 34% above |
SUPN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SUPN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.83 | $6.90 | +144% |
| 2021 | $6.90 | $17.8 | +157% |
| 2022 | $17.8 | $22.0 | +24% |
| 2023 | $22.0 | $15.3 | -31% |
| 2024 | $15.3 | $12.4 | -19% |
| 2025 | $12.4 | $36.2 | +192% |
| 2026 YTD | $36.2 | $29.2 | -19% |
SUPN has the edge over HIMS on returns for 2026, with the stronger performance.